>PFE RA drug Data looks really good. Interesting that the AE's and SAE's were actually numerically lower in the higher dose group. It's going to be all about long-term safety here. The biologics have a very good decade-long record despite initial worries about infections etc. Peter
Market Data 
Markets
AI
